Previous 10 | Next 10 |
2023-03-13 08:40:34 ET Mersana Therapeutics, a biotech focused on antibody-drug conjugates (ADC) fell ~14% Monday in the pre-market trading after announcing that the FDA has placed a clinical hold on its Phase 1 trial for cancer candidate XMT-2056. The decision comes after inv...
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced tha...
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an u...
Mersana Therapeutics, Inc. (MRSN) Q4 2022 Earnings Conference Call February 28, 2023, 08:00 AM ET Company Participants Jason Fredette - SVP, IR and Corporate Communications Anna Protopapas - President and CEO Arvin Yang - Chief Medical Officer Brian DeSchuytner - C...
Mersana Therapeutics press release ( NASDAQ: MRSN ): Q4 GAAP EPS of -$0.44 beats by $0.05 . Revenue of $14.69M (+146800.0% Y/Y) beats by $1.02M . For further details see: Mersana Therapeutics GAAP EPS of -$0.44 beats by $0.05, revenue of $14.69M beats by $1.02M
Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatin Initiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate, XMT-2056 Entered new research collaboration and commercial license agreement with ...
Mersana Therapeutics ( NASDAQ: MRSN ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is -$0.52 (+23.5% Y/Y) and the consensus Revenue Estimate is $13.67M (+136600.0% Y/Y). Over the last 3 months, EPS estim...
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...